+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vestibular Schwannoma Drug Pipeline Analysis Report 2025- Product Image
Vestibular Schwannoma Drug Pipeline Analysis Report 2025- Product Image
New

Vestibular Schwannoma Drug Pipeline Analysis Report 2025

  • PDF Icon

    Drug Pipelines

  • 200 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6102631
Description Jump to:
Vestibular schwannoma (VS) is a benign tumor that typically develops on the vestibulocochlear nerve, affecting hearing and balance. The disease accounts for approximately 6% of all intracranial tumors, with an estimated incidence of 3-5 per 100,000 individuals. There is a high unmet clinical need for better therapies to treat the disease, as current treatment options, such as surgery and radiation, often come with significant risks and side effects. Further, the growing focus on precision medicine and novel therapeutic approaches is likely to support pipeline growth in the coming years, offering hope for more effective and less invasive treatments.

Report Coverage

The Vestibular schwannoma Drug Pipeline Insight Report by the publisher gives comprehensive insights into vestibular schwannoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for vestibular schwannoma. The vestibular schwannoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The vestibular schwannoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from the condition, and alignment with vestibular schwannoma treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to vestibular schwannoma.

Vestibular Schwannoma Drug Pipeline Outlook

Vestibular schwannoma, also known as acoustic neuroma, is a benign tumor that develops on the vestibulocochlear nerve, which controls balance and hearing. This condition occurs when Schwann cells, responsible for producing the nerve's myelin sheath, grow abnormally. It typically affects adults and may cause symptoms like hearing loss, tinnitus, and balance issues. The tumor grows slowly and can compress adjacent brain structures, potentially leading to more severe complications.

Vestibular schwannoma treatment depends on tumor size, symptoms, and location. Options include observation for small tumors, surgical removal, and radiosurgery. Surgery aims to preserve hearing and facial nerve function while removing the tumor. Radiosurgery is a non-invasive alternative, particularly for smaller tumors. Early diagnosis and tailored treatment plans can help manage symptoms and reduce the risk of long-term complications.

Vestibular Schwannoma Epidemiology

A 2024 study found that the global incidence of vestibular schwannoma (VS) is 3-5 per 100,000 person-years. A 2023 study indicated that in the U.S., the incidence is 1.1 per 100,000 person-years, whereas Denmark reports a higher rate of 2.0 per 100,000. The condition is frequently associated with genetic factors and perinatal brain injuries. Regional prevalence varies, with higher rates observed in areas with advanced diagnostic capabilities and improved healthcare access.

Vestibular Schwannoma - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of vestibular schwannoma drug candidates based on several segmentations including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • Gene Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Vestibular Schwannoma - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total vestibular schwannoma clinical trials.

Vestibular Schwannoma - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the vestibular schwannoma pipeline analysis include small molecules, monoclonal antibodies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for vestibular schwannoma.

Vestibular Schwannoma Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the vestibular schwannoma report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Vestibular Schwannoma clinical trials:
  • Akouos, Inc.
  • Reveal Pharmaceuticals Inc.
  • Northwell Health

Vestibular Schwannoma - Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for vestibular schwannoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of vestibular schwannoma drug candidates.

Aspirin

The study, sponsored by the Massachusetts Eye and Ear Infirmary, aims to evaluate the effects of aspirin on slowing tumor growth and maintaining or improving hearing in patients with vestibular schwannoma. This Phase II, randomized, double-blind trial is expected to be completed by February 2029, enrolling approximately 300 participants. The objective is to assess whether aspirin can delay progression in these patients.

Crizotinib

Sponsored by the University of Alabama at Birmingham, this Phase 2 clinical trial investigates the efficacy of crizotinib in children and adults with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannomas. The study, expected to be concluded by December 2025, aims to enroll 19 participants and will assess clinical response using MRI volumetrics and audiology.

Reasons To Buy This Report

The Vestibular schwannoma Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for vestibular schwannoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within vestibular schwannoma pipeline insights.

Key Questions Answered in the Vestibular Schwannoma - Pipeline Insight Report

  • What is the current landscape of vestibular schwannoma pipeline drugs?
  • How many companies are developing vestibular schwannoma drugs?
  • How many phase III and phase IV drugs are currently present in vestibular schwannoma pipeline drugs?
  • Which companies/institutions are leading the vestibular schwannoma drug development?
  • What is the efficacy and safety profile of vestibular schwannoma pipeline drugs?
  • What are the opportunities and challenges present in the vestibular schwannoma drug pipeline landscape?
  • Which company is conducting major trials for vestibular schwannoma drugs?
  • What geographies are covered for vestibular schwannoma clinical trials?
  • What are emerging trends in vestibular schwannoma clinical trials?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Vestibular Schwannoma
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Vestibular Schwannoma
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Vestibular Schwannoma: Epidemiology Snapshot
5.1 Vestibular Schwannoma Incidence by Key Markets
5.2 Vestibular Schwannoma - Patients Seeking Treatment in Key Markets
6 Vestibular Schwannoma: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Vestibular Schwannoma: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Vestibular Schwannoma, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 Drug Pipeline Comparative Analysis
9.1 List of Vestibular Schwannoma Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Vestibular Schwannoma Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Methylprednisolone
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Other Drugs
11 Vestibular Schwannoma Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Aspirin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 NiMODipine Injectable Solution
11.2.3 Losartan
11.2.4 Crizotinib
11.2.5 Other Drugs
12 Vestibular Schwannoma Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug 1
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Vestibular Schwannoma Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Vestibular Schwannoma, Key Drug Pipeline Companies
14.1 Akouos, Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Reveal Pharmaceuticals Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Northwell Health
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region16 Terminated or Suspended Pipeline Products

Related Topics

Related Products

Vestibular Schwannoma - Pipeline Insight, 2025 - Product Image

Vestibular Schwannoma - Pipeline Insight, 2025

  • Clinical Trials
  • 50 Pages
  • Global
From
Vestibular Schwannoma Market - Product Image

Vestibular Schwannoma Market

  • Report
  • 250 Pages
  • Global
From
Oncolytic Virus - Competitive Landscape, 2022 - Product Image

Oncolytic Virus - Competitive Landscape, 2022

  • Report
  • 300 Pages
  • Global
From
Neuroendocrine Tumors Drug Pipeline Analysis Report 2025 - Product Image

Neuroendocrine Tumors Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Desmoid Tumors Drug Pipeline Analysis Report 2025 - Product Image

Desmoid Tumors Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.